MDNA 109Alternative Names: MDNA109
Latest Information Update: 06 Mar 2017
At a glance
- Originator Stanford University
- Developer Medicenna Therapeutics; Stanford University
- Class Antineoplastics; Interleukins; Recombinant proteins
- Mechanism of Action Interleukin-2 receptor agonists; Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer